AsianFin -- Merck has entered into a licensing agreement worth up to $2 billion with Jiangsu Hengrui Pharmaceuticals for a heart disease drug, marking the latest collaboration between U.S. pharmaceutical companies and Chinese firms.
Analysts note that major drugmakers like Merck and Eli Lilly are increasingly partnering with Chinese biotech companies to access innovative treatments at lower costs.
In a similar move, Danish pharmaceutical giant Novo Nordisk recently acquired global rights to a weight-loss drug candidate from China-based United Laboratories International in a deal valued at up to $2 billion.
Explore more exclusive insights at nextfin.ai.
